Developmental and molecular basis for a craniofacial metabolic syndrome

While causal genetic variants have been identified for many craniofacial syndromes, the functions of these genes in normal development and the mechanisms by which these variants lead to disease often remain unknown. Catel-Manzke syndrome (CMS) is a condition in which patients exhibit Pierre Robin Sequence (PRS), encompassing micrognathia and cleft secondary palate, together with limb and cardiovascular phenotypes and is caused by mutations in the dTDP-D-Glucose 4,6-dehydratase (TGDS)-encoding gene. The developmental and molecular functions of TGDS are unknown but our preliminary data indicate it may function in pathways impacting glycosaminoglycan metabolism. We have used next-generation CRISPR/Cas9 gene-editing approaches in mice to generate an allelic series that models CMS and enables the study of Tgds function in vivo. We propose a series of mouse genetic and quantitative morphometric assays to pinpoint the affected developmental processes, which we combine with unbiased transcriptomic, glycomic, and metabolomic approaches to build a foundation for understanding CMS etiology and Tgds developmental function. Completion of these studies will provide novel insights into the function of an unstudied gene, reveal the etiology of a craniofacial syndrome, and contribute to our fundamental understanding of how metabolic pathways regulate craniofacial development. Project Number: 5R21DE033889-02 | Fiscal Year: 2026 | NIH Institute/Center: National Institute of Dental and Craniofacial Research (NIDCR) | Principal Investigator: Jeffrey Bush (+1 co-PI) | Institution: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA | Award Amount: $190,576 | Activity Code: R21 | Study Section: Special Emphasis Panel[ZRG1-MSOS-L(03)M] View on NIH RePORTER: https://reporter.nih.gov/project-details/11270837